An Observational Study of Mircera in Patients With Chronic Renal Anemia on Dialysis (CKD Stage V) or Not on Dialysis (CKD Stage III-IV)

Hoffmann-La Roche78 enrolled

Overview

This observational study will evaluate the use and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in anemia patients with chronic kidney disease (CKD) stage III-IV not on dialysis or CKD stage V on dialysis. Patients will be followed during 12 months of treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Anemia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Patients with chronic renal anemia with stage III-IV CKD not on dialysis and who are, in the opinion of the treating physician, not expected at baseline to require dialysis within 12 months * Patients with chronic renal anemia with stage V CKD on dialysis * No contraindication to ESA treatment Exclusion Criteria: * Uncontrolled hypertension * Hypersensitivity to the active substance or any other of the excipients of Mircera and other ESAs

Locations (1)

Unnamed facility

Podgorica, Montenegro

Outcomes

Primary Outcomes

Dosage/schedule of Mircera treatment in clinical practice

Time frame: approximately 3 years

Secondary Outcomes

Proportion of patients with mean Hb level 10-12 g/dL 10 to 12 months after initiation of treatment

Time frame: approximately 3 years

Change in Hb levels

Time frame: from baseline to Month 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.